← Back to Search

18F-αvβ6-BP for Cancer

Phase < 1
Waitlist Available
Led By Julie Sutcliffe
Research Sponsored by Julie L. Sutcliffe, Ph.D
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with primary or metastatic cancer in one or more of the following locations: breast, colorectal, lung, pancreas
Eastern Cooperative Oncology Group (ECOG) performance score of 0-1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Study Summary

This trial studies the side effects of a radiotracer called 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic.

Who is the study for?
This trial is for people with primary or metastatic breast, colorectal, lung, or pancreatic cancer who can stay still for PET scans and have a good performance status. It's not for those with severe kidney/liver issues, very short life expectancy, pregnant/breastfeeding women, recent investigational drug use, or inability to undergo PET/CT scans.Check my eligibility
What is being tested?
The study tests the safety and imaging effectiveness of a radiotracer called 18F-αvβ6-binding-peptide in detecting cancers such as breast, colorectal, lung and pancreatic when used during PET scans.See study design
What are the potential side effects?
Specific side effects are not listed but generally include potential reactions to the radiotracer like rash or discomfort at injection site. The scan procedure may cause discomfort from staying still.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer is in the breast, colorectal, lung, or pancreas.
Select...
I am fully active or have some restrictions but can still care for myself.
Select...
I can stay still for up to an hour.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assessment of safe administration of 18F-αvβ6-BP
Secondary outcome measures
Level of αvβ6-BP expression in tumors
Measurement of 18F-αvβ6-BP accumulation in tumors

Trial Design

1Treatment groups
Experimental Treatment
Group I: 18F-αvβ6-BPExperimental Treatment1 Intervention
Patients receive 18F-alphavbeta6-BP IV and then undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection.

Find a Location

Who is running the clinical trial?

Julie L. Sutcliffe, Ph.DLead Sponsor
National Cancer Institute (NCI)NIH
13,657 Previous Clinical Trials
40,933,640 Total Patients Enrolled
Julie SutcliffePrincipal InvestigatorUniversity of California, Davis
1 Previous Clinical Trials

Media Library

18F-αvβ6-BP Clinical Trial Eligibility Overview. Trial Name: NCT03164486 — Phase < 1
Lung Cancer Research Study Groups: 18F-αvβ6-BP
Lung Cancer Clinical Trial 2023: 18F-αvβ6-BP Highlights & Side Effects. Trial Name: NCT03164486 — Phase < 1
18F-αvβ6-BP 2023 Treatment Timeline for Medical Study. Trial Name: NCT03164486 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
Julie L. Sutcliffe, Ph.D 2016. "First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03164486.
All > Colon Cancer
~2 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top